QCG
ICPT

Quadrant Capital Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Quadrant Capital Group’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-64
Closed -$1K – 2886
2022
Q3 		$1K Buy
+64
New +$1.03K ﹤0.01% 2601
2022
Q1 		– Sell
-571
Closed -$9K – 2751
2021
Q4 		$9K Sell
571
-8
-1% -$135 ﹤0.01% 1697
2021
Q3 		$9K Buy
+579
New +$9.26K ﹤0.01% 1673
2021
Q2 		– Sell
-9
Closed – – 2618
2021
Q1 		$0 Sell
9
-6
-40% -$167 ﹤0.01% 2485
2020
Q4 		$0 Buy
+15
New +$497 ﹤0.01% 2403
2019
Q3 		– Sell
-279
Closed -$22K – 2414
2019
Q2 		$22K Buy
+279
New +$25K ﹤0.01% 1617
2017
Q2 		– Sell
-44
Closed -$4K – 2110
2017
Q1 		$4K Sell
44
-152
-78% -$17.7K ﹤0.01% 1436
2016
Q4 		$21K Sell
196
-44
-18% -$5.24K 0.01% 745
2016
Q3 		$38K Buy
240
+198
+471% +$31.2K 0.02% 529
2016
Q2 		$5K Buy
+42
New +$6.12K ﹤0.01% 1245
2016
Q1 		– Sell
-60
Closed -$8K – 2043
2015
Q4 		$8K Buy
+60
New +$10.2K 0.01% 885

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Quadrant Capital Group's ICPT Position: Q4 2022 in Review

Quadrant Capital Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2022, closing a stake of 64 shares — an estimated $1K sold.

Quadrant Capital Group first reported a position in ICPT in Q4 2015 and held it in 11 quarters. The position peaked at $38K in Q3 2016. 144 funds tracked by Wall St. Rank hold ICPT as of Q4 2022.

  • Quadrant Capital Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Quadrant Capital Group sold 64 Intercept Pharmaceuticals, Inc. shares in Q4 2022, an estimated $1K.
  • Quadrant Capital Group first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2015 and held it in 11 quarters.
  • Quadrant Capital Group's Intercept Pharmaceuticals, Inc. position peaked at $38K in Q3 2016.
  • 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2022.

Based on Quadrant Capital Group's 13F filing for Q4 2022, filed 13 Feb 2023.